A Phase 3 interventional study of Denosumab in Osteogenesis Imperfecta, sponsored by Amgen. Terminated at 49 sites in 13 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-12-28.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Osteogenesis Imperfecta with a site in United States — 4 open to participants now, 11 under way, 4 of them phase 3. Osteogenesis Imperfecta · United States.
Among the 38 studies in Osteogenesis Imperfecta with a site in United States, this one is the 3rd largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 15th registered.
84 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.
Browse Osteogenesis Imperfecta studies →4 of the 38 studies in Osteogenesis Imperfecta with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States, Germany, Japan
Ages 5–19
Angitia Incorporated Limited · Sites in United States, Argentina, Australia and 5 more countries
Ages 18–75
Hospital for Special Surgery, New York · Sites in United States
Ages 6–100 · Healthy volunteers
Baylor College of Medicine · Sites in United States, Canada
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Osteogenesis Imperfecta studies recruiting now, 4 (29%) set no upper age limit and 8 (57%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 9 · Phase 4 2
First in 1991; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 28 across 60 interventional studies indexed under Osteogenesis Imperfecta.
Median enrollment 63 across the 28 interventional studies, 82 across the 10 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 38 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 5 studies filed under Osteogenesis Imperfecta — fewer than ten, so there is no comparison to draw.
5 of the studies in Osteogenesis Imperfecta with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05972551Phase 3AmgenStudy to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta | 2027-05-04 |
| NCT04152551Hospital for Special Surgery, New YorkEffects of Bisphosphonates on OI-Related Hearing Loss | 2027-01 |
| NCT04815564Baylor College of MedicineClear Aligners for the Treatment of Dental Malocclusion in OI | 2027-08-01 |
| NCT05317637Baylor College of MedicineCardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708 | 2027-08-31 |
| NCT07062588Angitia Incorporated LimitedOsteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 38 studies in Osteogenesis Imperfecta with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.
To evaluate the effect of denosumab in lumbar spine bone mineral density (BMD) Z-score at 12 months, as assessed by dual-energy X-ray absorptiometry (DXA), in children 2 to 17 years of age (at the time of screening) on a 3-Month Dosing Regimen with osteogenesis imperfecta (OI)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria:
Exclusion Criteria:
Prior treatment with
Administration of any of the following treatment within 3 months of screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received denosumab 1 mg/kg (up to a maximum of 60 mg) subcutaneously every 6 months (Q6M) for up to 36 months. Early efficacy and PK data from Q6M dosing supported adjustment of the dosing regimen from Q6M to every 3 months (Q3M). Participants enrolled and still receiving denosumab were transitioned from Q6M to Q3M dosing schedule. Participants could transition to Q3M dosing schedule up to and including the date they attended for their month 36 visit under the Q6M dosing regimen. Those participants received denosumab during the Q3M dosing regimen for 12 months. Participants who transition to Q3M at month 18 of the Q6M dosing regimen received denosumab Q3M for up to 18 months.
Drug: Denosumab
Subcutaneous (SC) injection.
Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score at 12 Months
Lumbar spine BMD was measured by dual-energy X-ray absorptiometry (DXA) adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.
Time frame: Baseline and 12 months
Change From Baseline in Lumbar Spine BMD Z-score at 6 Months
Lumbar spine BMD was measured by DXA adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.
Time frame: Baseline and 6 months
Change From Baseline in Proximal Femur BMD Z-score at 6 and 12 Months
Proximal femur (total hip and femoral neck) BMD Z-score was measured by DXA adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.
Time frame: Baseline, 6 and 12 months
Percentage of Participants With at Least 1 X-ray Confirmed Long Bone or New and Worsening Vertebral Fracture
Time frame: Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months
Percentage of Participants With at Least 1 X-ray Confirmed New and Worsening Vertebral Fracture
Time frame: Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months
Percentage of Participants With at Least 1 X-ray Confirmed New Vertebral Fracture
Time frame: Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months
Percentage of Participants Wth at Least 1 X-ray Confirmed Improving Vertebral Fracture
Time frame: Q3M Dosing Regimen: Baseline up to 12 months
Percentage of Participants With at Least 1 Vertebral and Nonvertebral Fracture
Time frame: Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months
Change From Baseline in Child Health Questionnaire-Parent Form Physical Summary Score (CHQ-PF-50) at 12 Months
The CHQ-PF-50 was a 50-item questionnaire completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A negative change from Baseline indicates decreased well-being.
Time frame: Baseline and 12 months
Change From Baseline in CHQ-PF-50 Psychological Summary Score at 12 Months
The CHQ-PF-50 was a 50-item questionnaire completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A positive change from Baseline indicates improved well-being.
Time frame: Baseline and 12 months
Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12 Months
The disability domain (questions 1-54) of the CHAQ was used to measure the participant's assessment of physical functioning or the parent's assessment of the child's physical functioning. The disability index comprised of 8 categories (dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and activities). Scoring ranged from 1 to 5; 1 was "without any difficulty," 2 was "with some difficulty," 3 was "with much difficulty," and 4 was "unable to do." An answer of "not applicable" was scored as a 5, but was not counted. If a child required assistance from another person or used an aid or other device for any of the 8 categories, the minimum score for that category was recorded as a 3. The CHAQ questions were scored and converted to a total index score ranging from 0 to 3. Negative change from Baseline indicates an improvement.
Time frame: Baseline and 12 months
Change From Baseline in Wong-Baker Faces Pain Rating Scale (WBFPRS) at 12 Months
Participants were asked to report their level of pain by choosing a face that best described their own pain (the corresponding number: 0, 2, 4, 6, 8, 10) were then recorded. The WBFPRS ranged from 0, "no hurt," to 10, "hurts worst". A negative change from baseline indicates an improvement.
Time frame: Baseline and 12 months
Serum Concentration of Denosumab
Time frame: Days 1 (predose), 10, 30, and 60, & weeks 12, 24, 36, 48, 60, 72 (end of study visit), early termination visit, & follow-up visit 12 weeks after last dose (average duration of treatment: 231 days)
Serum Bone Turnover Marker (BTM) - Serum Type I Collagen C Telopeptide
Time frame: Baseline and Days 10 and 30, and Months 3, 6, 9, 12, 15 and 18
BTM - Bone-specific Alkaline Phosphatase (BSAP)
Time frame: Baseline and Days 10 and 30, and Months 3, 6, 9, 12, and 15
Change From Baseline in Growth Velocity at 12 Months
Change from baseline in growth velocity was determined by calculating age-adjusted Z-scores for height, weight and body mass index (BMI). Height-for-age Z-score was defined as the difference between the participant's height and the median height for the population with the same age and gender, divided by the population standard deviation. The definitions of growth velocity based on weight and BMI were analogously calculated. To programmatically calculate the Z-scores, the National Center for Health Statistics percentiles growth charts, based on the 2000 Center for Disease Control and Prevention (CDC) (http://www.cdc.gov/growthcharts/c c_charts.htm), and the CDC Anthropometric Software Package 3.0 Z-scores were used. During normal growth, the change in z-score for each of the three should equal 0. A positive change in any of the three indicates growth acceleration, whereas a negative change indicates deceleration.
Time frame: Baseline and 12 months
The study was conducted at 32 centers in North America, Europe, and Australia from June 2015 to March 2022.
| Milestone | Denosumab |
|---|---|
| Started | 153 |
| Received investigational product | 153 |
| Completed | 55 |
| Not completed | 98 |
| Withdrew: Decision by sponsor | 2 |
| Withdrew: Withdrawal by subject | 34 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Transitioning to q3m | 60 |
| Milestone | Denosumab |
|---|---|
| Started | 60 |
| Received investigational product | 60 |
| Completed | 40 |
| Not completed | 20 |
| Withdrew: Decision by sponsor | 14 |
| Withdrew: Withdrawal by subject | 6 |
Lumbar spine BMD was measured by dual-energy X-ray absorptiometry (DXA) adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.
| Z-score | Denosumab 3-Month Dosing Regimen |
|---|---|
| Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score at 12 Months | 1.009 ± 0.119 |
Lumbar spine BMD was measured by DXA adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.
| Z-score | Denosumab 3-Month Dosing Regimen |
|---|---|
| Change From Baseline in Lumbar Spine BMD Z-score at 6 Months | 0.925 ± 0.078 |
Proximal femur (total hip and femoral neck) BMD Z-score was measured by DXA adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.
| Z score | Denosumab 3-Month Dosing Regimen |
|---|---|
| Total hip BMD Z-score - 6 Months | 0.799 ± 0.082 |
| Total hip BMD Z-score - 12 Months | 0.793 ± 0.154 |
| Femoral neck BMD Z-score - 6 Months | 0.769 ± 0.067 |
| Femoral neck BMD Z-score - 12 Months | 0.689 ± 0.131 |
| Percentage of participants | Denosumab 6-Month Dosing Regimen | Denosumab 3-Month Dosing Regimen |
|---|---|---|
| Percentage of Participants With at Least 1 X-ray Confirmed Long Bone or New and Worsening Vertebral Fracture | 28.3 | 26.7 |
| Percentage of participants | Denosumab 6-Month Dosing Regimen | Denosumab 3-Month Dosing Regimen |
|---|---|---|
| Percentage of Participants With at Least 1 X-ray Confirmed New and Worsening Vertebral Fracture | 12.8 | 8.5 |
| Percentage of participants | Denosumab 6-Month Dosing Regimen | Denosumab 3-Month Dosing Regimen |
|---|---|---|
| Percentage of Participants With at Least 1 X-ray Confirmed New Vertebral Fracture | 10.6 | 6.4 |
| Percentage of participants | Denosumab 3-Month Dosing Regimen |
|---|---|
| Percentage of Participants Wth at Least 1 X-ray Confirmed Improving Vertebral Fracture | 27.7 |
| Percentage of participants | Denosumab 6-Month Dosing Regimen | Denosumab 3-Month Dosing Regimen |
|---|---|---|
| Percentage of Participants With at Least 1 Vertebral and Nonvertebral Fracture | 28.6 | 30.4 |
The CHQ-PF-50 was a 50-item questionnaire completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A negative change from Baseline indicates decreased well-being.
| Score on a scale | Denosumab 3-Month Dosing Regimen |
|---|---|
| Change From Baseline in Child Health Questionnaire-Parent Form Physical Summary Score (CHQ-PF-50) at 12 Months | -0.98 ± 15.41 |
The CHQ-PF-50 was a 50-item questionnaire completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A positive change from Baseline indicates improved well-being.
| Score on a scale | Denosumab 3-Month Dosing Regimen |
|---|---|
| Change From Baseline in CHQ-PF-50 Psychological Summary Score at 12 Months | 0.85 ± 8.57 |
The disability domain (questions 1-54) of the CHAQ was used to measure the participant's assessment of physical functioning or the parent's assessment of the child's physical functioning. The disability index comprised of 8 categories (dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and activities). Scoring ranged from 1 to 5; 1 was "without any difficulty," 2 was "with some difficulty," 3 was "with much difficulty," and 4 was "unable to do." An answer of "not applicable" was scored as a 5, but was not counted. If a child required assistance from another person or used an aid or other device for any of the 8 categories, the minimum score for that category was recorded as a 3. The CHAQ questions were scored and converted to a total index score ranging from 0 to 3. Negative change from Baseline indicates an improvement.
| Score on a scale | Denosumab 3-Month Dosing Regimen |
|---|---|
| Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12 Months | -0.06 ± 0.46 |
Participants were asked to report their level of pain by choosing a face that best described their own pain (the corresponding number: 0, 2, 4, 6, 8, 10) were then recorded. The WBFPRS ranged from 0, "no hurt," to 10, "hurts worst". A negative change from baseline indicates an improvement.
| Score on a scale | Denosumab 3-Month Dosing Regimen |
|---|---|
| Change From Baseline in Wong-Baker Faces Pain Rating Scale (WBFPRS) at 12 Months | 0.0 ± 1.7 |
| ng/mL | Denosumab 3-Month Dosing Regimen |
|---|---|
| Day 1 | 8.1 ± 62.0 |
| Day 10 | 6685.4 ± 1761.8 |
| Day 30 | 3840.5 ± 1329.9 |
| Day 60 | 1291.4 ± 971.2 |
| Week 12 Day 1 | 406.2 ± 627.0 |
| Week 24 Day 1 | 589.8 ± 804.3 |
| Week 36 | 835.1 ± 983.5 |
| Week 48 | 647.3 ± 875.1 |
| Week 60 | 1266.7 ± 861.1 |
| Week 72 | 970.0 ± 1371.8 |
| Early Termination Visit | 4.2 ± 11.8 |
| Week 12 Follow-up Visit | 72.6 ± 103.9 |
| ng/L | Denosumab 3-Month Dosing Regimen |
|---|---|
| Baseline | 1136.5 ± 569.7 |
| Day 10 | 174.4 ± 64.7 |
| Day 30 | 176.5 ± 87.9 |
| Month 3 | 498.4 ± 332.0 |
| Month 6 | 537.1 ± 427.1 |
| Month 9 | 539.0 ± 425.0 |
| Month 12 | 681.2 ± 563.1 |
| Month 15 | 1050.8 ± 758.8 |
| Month 18 | 1290.0 ± NA |
| μg/L | Denosumab 3-Month Dosing Regimen |
|---|---|
| Baseline | 69.22 ± 34.26 |
| Day 10 | 70.88 ± 32.77 |
| Day 30 | 56.28 ± 28.32 |
| Month 3 | 498.4 ± 332.0 |
| Month 6 | 40.30 ± 22.58 |
| Month 9 | 51.17 ± 106.27 |
| Month 12 | 40.02 ± 27.64 |
| Month 15 | 49.49 ± 31.20 |
Change from baseline in growth velocity was determined by calculating age-adjusted Z-scores for height, weight and body mass index (BMI). Height-for-age Z-score was defined as the difference between the participant's height and the median height for the population with the same age and gender, divided by the population standard deviation. The definitions of growth velocity based on weight and BMI were analogously calculated. To programmatically calculate the Z-scores, the National Center for Health Statistics percentiles growth charts, based on the 2000 Center for Disease Control and Prevention (CDC) (http://www.cdc.gov/growthcharts/c c_charts.htm), and the CDC Anthropometric Software Package 3.0 Z-scores were used. During normal growth, the change in z-score for each of the three should equal 0. A positive change in any of the three indicates growth acceleration, whereas a negative change indicates deceleration.
| Z-score | Denosumab 3-Month Dosing Regimen |
|---|---|
| Height -for-age Z-score | -0.01 ± 0.43 |
| Weight-for-age Z-score | 0.01 ± 0.53 |
| BMI-for-age Z-score | -0.07 ± 0.52 |
Collected over 6QM dosing regimen: Day 1 up to 36 months 3QM dosing regimen: Day 1 up to 24 weeks after last dose (median duration of treatment was 253 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab 6-Month Dosing Regimen | 0/153 (0%) | 52/153 (34%) | 141/153 (92.2%) |
| Denosumab 3-Month Dosing Regimen | 0/60 (0%) | 12/60 (20%) | 38/60 (63.3%) |
| Event | Denosumab 6-Month Dosing Regimen | Denosumab 3-Month Dosing Regimen |
|---|---|---|
| HypercalcaemiaMetabolism and nutrition disorders | 0/153 | 8/60 |
| Femur fractureInjury, poisoning and procedural complications | 15/153 | 2/60 |
| Tibia fractureInjury, poisoning and procedural complications | 10/153 | 2/60 |
| Humerus fractureInjury, poisoning and procedural complications | 8/153 | 0/60 |
| Fibula fractureInjury, poisoning and procedural complications | 7/153 | 1/60 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 5/153 | 0/60 |
| Radius fractureInjury, poisoning and procedural complications | 5/153 | 1/60 |
| Ulna fractureInjury, poisoning and procedural complications | 4/153 | 1/60 |
| Device dislocationProduct Issues | 4/153 | 0/60 |
| General physical health deteriorationGeneral disorders | 0/153 | 1/60 |
| Event | Denosumab 6-Month Dosing Regimen | Denosumab 3-Month Dosing Regimen |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 70/153 | 15/60 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 57/153 | 11/60 |
| Back painMusculoskeletal and connective tissue disorders | 50/153 | 5/60 |
| HypercalciuriaRenal and urinary disorders | 49/153 | 5/60 |
| HypercalcaemiaMetabolism and nutrition disorders | 28/153 | 15/60 |
| FallInjury, poisoning and procedural complications | 25/153 | 6/60 |
| NasopharyngitisInfections and infestations | 23/153 | 7/60 |
| Bone painMusculoskeletal and connective tissue disorders | 21/153 | 1/60 |
| HeadacheNervous system disorders | 21/153 | 4/60 |
| PyrexiaGeneral disorders | 18/153 | 1/60 |
The full analysis set (FAS) included all participants who enrolled into the study.
| Age, Continuous(Years) | Denosumab |
|---|---|
| Mean | 9.3 ± 3.9 |
| Sex: Female, Male(Participants) | Denosumab |
|---|---|
| Female | 73 |
| Male | 80 |
| Ethnicity (NIH/OMB)(Participants) | Denosumab |
|---|---|
| Hispanic or Latino | 15 |
| Not Hispanic or Latino | 138 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Denosumab |
|---|---|
| Asian | 4 |
| Black or African American | 2 |
| White | 135 |
| Other | 8 |
| Multiple | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jun 2015 to primary completion in Mar 2022, 81 months.
Results were first posted in Dec 2022, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab